

Name of Journal: *World Journal of Clinical Cases*

Manuscript Type: CASE REPORT

Title: Metastatic gastric cancer from breast carcinoma presenting with a rheumatic paraneoplastic syndrome

Authors: *Marília Bortoluz Rech. Eduarda Renz da Cruz. Karina Salgado, PhD., MD. Raul Angelo Balbinot, PhD, MD. Silvana Sartori Balbinot, PhD, MD. Jonathan Soldera, Prof, MSc, MD.*

Corresponding Author: Jonathan Soldera, Professor of Clinical Gastroenterology, School of Medicine, Universidade de Caxias do Sul, Ver Mário Pezzi Av, 699/801, Caxias do Sul - RS, CEP 95084-180, Brazil, Tel: 54-3039-3165; Email: jonathansoldera@gmail.com

ANSWER TO REVIEWERS

REVIEWER 1:

This manuscript reported a signet-ring cell adenocarcinoma with a metastasis of a breast carcinoma. The case is extremely rare and has great clinically significant.

We would like to thank for the opportunity to improve our manuscript. Thank you for your valuable input.

REVIEWER 2:

In this manuscript, the authors made a case report of metastatic gastric cancer from breast carcinoma presenting with a rheumatic paraneoplastic syndrome.

The case was rare and could help us understand the biological, pathological and therapeutic choice for gastric metastasis from breast cancer. Several suggestions are as follows.

Thank you for your suggestions and the opportunity to improve our manuscript.

1. Please add the information of the molecular subtypes of breast cancer and metastatic gastric cancer, including ER, PR, HER2, Ki67.

We have added a sentence describing the full immunohistochemistry report.

2. If the IHC for ER is positive, why not choose endocrine therapy plus CDK4/6 inhibitor? Because the endocrine therapy is the standard therapy for metastatic ER+ breast cancer.

She began treatment with endocrine therapy, but it failed to control the disease. We have described this in the paper now.

3. Any other sites of metastasis? Visceral or bone metastasis?

Yes, she had bone metastasis, as we have described in the paper.

REVIEWER 3:

Thank you for your suggestions and the opportunity to improve our manuscript.

1. The author should show the methods of treatment, including the chemotherapy regimen, usage and dosage of prednisone;

We have described the dose of prednisone and the regimen of chemotherapy.

2. The efficacy also needs to be described and provide evidence;

We have added data on her laboratory results.

3. It is better to mark the gastroscopy pictures for more intuitive.

Thank you for your suggestion. We have added an arrow marking the erosion.